World Heath Organization. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed 3/3/25.

Valenzuela PL, Carrera-Bastos P, Castillo-García A, Lieberman DE, Santos-Lozano A, Lucia A (2023) Obesity and the risk of cardiometabolic diseases. Nat Rev Cardiol 20(7):475–494

Article  PubMed  Google Scholar 

Yuen MMA (2023) Health complications of obesity: 224 obesity-associated comorbidities from a mechanistic perspective. Gastroenterol Clin North Am 52(2):363–380

Arterburn DE, Telem DA, Kushner RF, Courcoulas AP (2020) Benefits and risks of bariatric surgery in adults: a review. JAMA 324:879–887

Article  PubMed  Google Scholar 

Courcoulas AP, Patti ME, Hu B, Arterburn DE, Simonson DC, Gourash WF et al (2024) Long-term outcomes of medical management vs bariatric surgery in type 2 diabetes. JAMA 331:654–664

Article  PubMed  PubMed Central  Google Scholar 

Perdomo CM, Cohen RV, Sumithran P, Clément K, Frühbeck G (2023) Contemporary medical, device, and surgical therapies for obesity in adults. Lancet 401(10382):1116–1130

Article  PubMed  Google Scholar 

Papageorgiou M, Kerschan-Schindl K, Sathyapalan T, Pietschmann P (2020) Is weight loss harmful for skeletal health in obese older adults? Gerontology 66(1):2–14

Article  PubMed  Google Scholar 

Paccou J, Caiazzo R, Lespessailles E, Cortet B (2022) Bariatric surgery and osteoporosis. Calcif Tissue Int 110:576–591

Article  PubMed  CAS  Google Scholar 

Zibellini J, Seimon RV, Lee CM et al (2015) Does diet-induced weight loss lead to bone loss in overweight or obese adults? A systematic review and meta-analysis of clinical trials. J Bone Miner Res 30(12):2168–2178

Article  PubMed  CAS  Google Scholar 

Gagnon C, Schafer AL (2018) Bone Health After Bariatric Surgery. JBMR Plus 2(3):121–133

Article  PubMed  PubMed Central  Google Scholar 

Lindeman KG, Greenblatt LB, Rourke C et al (2018) Longitudinal 5-year evaluation of bone density and microarchitecture after Roux-en-Y gastric bypass surgery. J Clin Endocrinol Metab 103:4104–4112

Article  PubMed  PubMed Central  Google Scholar 

Paccou J, Martignène N, Lespessailles E et al (2020) Gastric Bypass But Not Sleeve Gastrectomy Increases Risk of Major Osteoporotic Fracture: French Population-Based Cohort Study. J Bone Miner Res 35(8):1415–1423

Article  PubMed  CAS  Google Scholar 

Herrou J, Mabilleau G, Lecerf JM, Thomas T, Biver E, Paccou J (2024) Narrative review of effects of Glucagon-Like Peptide-1 Receptor Agonists on bone health in people living with obesity. Calcif Tissue Int 114(2):86–97

Article  PubMed  CAS  Google Scholar 

Gautier JF, Choukem SP, Girard J (2008) Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes Metab 34(Suppl 2):S65-72

Article  PubMed  CAS  Google Scholar 

Bass J, Tschöp MH, Beutler LR (2023) Dual gut hormone receptor agonists for diabetes and obesity. J Clin Invest 133(3):e167952

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kusminski CM, Perez-Tilve D, Müller TD, DiMarchi RD, Tschöp MH, Scherer PE (2024) Transforming obesity: The advancement of multi-receptor drugs. Cell 187(15):3829–3853

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wolfe MM, Boylan MO, Chin WW (2025) Glucose-dependent insulinotropic polypeptide in incretin physiology: role in health and disease. Endocr Rev 46(4):479–500. https://doi.org/10.1210/endrev/bnaf006

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wilding JPH, Batterham RL, Calanna S et al (2021) Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 384(11):989–1002

Article  PubMed  CAS  Google Scholar 

Davies M, Færch L, Jeppesen OK et al (2021) Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 397(10278):971–984

Article  PubMed  CAS  Google Scholar 

Shi I, Khan SS, Yeh RW, Ho JE, Dahabreh IJ, Kazi DS (2025) Semaglutide Eligibility Across All Current Indications for US Adults. JAMA Cardiol 10(1):96–98

Article  PubMed  Google Scholar 

Haddy N, Jourdain H, Desplas D, Bertrand M, Jabagi MJ, Rives-Lange C, Zureik M (2025) Use of semaglutide (Wegovy) in adults in France: A nationwide drug utilization study. BioDrugs 39(2):321–332. https://doi.org/10.1007/s40259-024-00699-6

Article  PubMed  CAS  Google Scholar 

Hamza M, Papamargaritis D, Davies MJ (2025) Tirzepatide for overweight and obesity management. Expert Opin Pharmacother 26(1):31–49

Article  PubMed  CAS  Google Scholar 

Jastreboff AM, Aronne LJ, Ahmad NN et al (2022) Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 387(3):205–216

Article  PubMed  CAS  Google Scholar 

Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, Wilding JPH, Perreault L, Zhang S, Battula R, Bunck MC, Ahmad NN, Jouravskaya I (2025) SURMOUNT-1 investigators. tirzepatide for obesity treatment and diabetes prevention. N Engl J Med 6 392(10):958–971

Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, Ma X, Mather KJ, Haupt A, Robins D, Pratt E, Kazda C, Konig M; GZGI Investigators (2023) Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med 389(10):877–888

Jastreboff AM, Kaplan LM, Frías JP et al (2023) Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med 389(6):514–526

Article  PubMed  CAS  Google Scholar 

Drucker DJ (2025) Discovery of GLP-1-Based Drugs for the Treatment of Obesity. N Engl J Med 392(6):612–615

Article  PubMed  Google Scholar 

Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T (2023) Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet 402(10401):529–544

Article  PubMed  CAS  Google Scholar 

Papageorgiou M, Biver E (2023) Bone consequences of intentional weight loss in overweight or obese patients. Rev Med Suisse 19:756–760

PubMed  Google Scholar 

Armamento-Villareal R, Aguirre L, Waters DL, Napoli N, Qualls C, Villareal DT (2020) Effect of aerobic or resistance exercise, or both, on bone mineral density and bone metabolism in obese older adults while dieting: a randomized controlled trial. J Bone Miner Res 35:430–439

Article  PubMed  CAS  Google Scholar 

Pines A (2012) Weight loss, weight regain and bone health. Climacteric 15:317–319

Article  PubMed  Google Scholar 

Villareal DT, Shah K, Banks MR, Sinacore DR, Klein S (2008) Effect of weight loss and exercise therapy on bone metabolism and mass in obese older adults: a one-year randomized controlled trial. J Clin Endocrinol Metab 93(6):2181–2187

Article  PubMed  PubMed Central  CAS  Google Scholar 

Johnson KC, Bray GA, Cheskin LJ, Clark JM, Egan CM, Foreyt JP et al (2017) The effect of intentional weight loss on fracture risk in persons with diabetes: results from the Look AHEAD randomized clinical trial. J Bone Miner Res 32(11):2278–2287

Article  PubMed  Google Scholar 

Lespessailles E, Paccou J, Javier RM et al (2019) GRIO Scientific Committee Obesity, bariatric surgery, and fractures. J Clin Endocrinol Metab 104:4756–4768

Article  PubMed  Google Scholar 

Paccou J, Tsourdi E, Meier C, Palermo A, Pepe J, Body JJ, Zillikens MC (2022) Bariatric surgery and skeletal health: a narrative review and position statement for management by the European Calcified Tissue Society (ECTS). Bone 154:116236

Article  PubMed